Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
Antiangiogenic therapy is a promising alternative for prostate cancer growth and metastasis and holds great promise as an adjuvant therapy. The present study evaluated the potential of stable expression of angiostatin and endostatin before the onset of neoplasia and during the early and late stages of prostate cancer progression in transgenic adenocarcinoma of mouse prostate (TRAMP) mice. Groups of 5-, 10-, and 18-week-old male TRAMP mice received recombinant adeno-associated virus-6 encoding mouse endostatin plus angiostatin (E+A) by i.m. injection. The effects of therapy were determined by sacrificing groups of treated mice at defined stages of tumor progression and following cohorts of similarly treated mice for long-term survival. Results indicated remarkable survival after recombinant adeno-associated virus-(E+A) therapy only when the treatment was given at an earlier time, before the onset of high-grade neoplasia, compared with treatment given for invasive cancer. Interestingly, early-stage antiangiogenic therapy arrested the progression of moderately differentiated carcinoma to poorly differentiated state and distant metastasis. Immunohistochemical analysis of the prostate from treated mice indicated significantly lower endothelial cell proliferation and increased tumor cell apoptosis. Vascular endothelial growth factor receptor (VEGFR)-2 expression was significantly down-regulated in tumor endothelium after treatment but not VEGFR-1. Analysis of the neuroendocrine marker synaptophysin expression indicated that antiangiogenic therapy given at an early-stage disease reduced neuroendocrine transition of the epithelial tumors. These studies indicate that stable endostatin and angiostatin gene therapy may be more effective for minimally invasive tumors rather than advanced-stage disease.
Isayeva
Tatyana
T
Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama 35294-0007, USA.
Chanda
Diptiman
D
Kallman
Lisa
L
Eltoum
Isam-Eldin A
IE
Ponnazhagan
Selvarangan
S
D000230:Adenocarcinoma / Q000628:therapy*; D000256:Adenoviridae / Q000235:genetics; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D043168:Angiostatins / Q000008:administration & dosage* / Q000235:genetics; D000818:Animals; D004195:Disease Models, Animal; D043169:Endostatins / Q000008:administration & dosage* / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011471:Prostatic Neoplasms / Q000628:therapy*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016708:Synaptophysin / Q000187:drug effects / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D043169:Endostatins; D016708:Synaptophysin; D043168:Angiostatins; D040262:Receptors, Vascular Endothelial Growth Factor